Skip to main content

Table 4 Changes in the median (range) blood Phe:Tyr ratio within and between the CGMP-AA2 and Phe-free L-AA group at baseline, 26 and 52 weeks

From: Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU

Group

Number of subjects

Baseline (range)

Wk 26 (range)

Wk 52 (range)

P value

CGMP-AA2

29

5.7§* (1.5–11)

6.4§ (1.3–11.7)

6.4* (1.7–11.5)

§p = 0.010 *p < 0.010

Phe-free L-AA

19

7.2§§** (3.1–15)

6.8§§ (3–11.7)

7.4** (4–15.1)

§§p = 0.555 **p = 0.246

  1. Wilcoxon test § GMP baseline to 26 wk., * GMP baseline to 52 wk
  2. Wilcoxon test §§ L-AA baseline to 26 wk., ** L-AA baseline to 52 wk
  3. ABREVIATIONS: CGMP-AA low phenylalanine glycomacropeptide protein substitute supplemented with L-amino acids, Phe-free L-AA Phenylalanine free L-amino acid supplement